Biotech & Genomic Medicine▲
Biotech Stocks Hit 52-Week Highs on Trial Results and Acquisitions
Several biotech stocks reached 52-week highs on July 22, 2026, driven by clinical trial updates and acquisition news. Advanced Biomed shares surged over 73% to $18.73 after reporting a first-quarter net income of $5.98 million and disclosing a securities purchase agreement to acquire Accellent Technologies for approximately $1 million. BioLife Solutions rose over 6% to $31.49 following the announcement that Repligen would acquire the company for a total enterprise value of about $1.5 billion. Forte Biosciences gained over 11% to $56.84 after reporting positive Phase 1 vitiligo trial results for its lead product FB102, which is also in Phase 2 for celiac disease. Silence Therapeutics climbed over 9% to $11.90 as it prepares to begin a Phase 3 trial for its siRNA candidate Zerlasiran in high-risk atherosclerotic cardiovascular disease. LB Pharmaceuticals ended up over 10% at $36.59 after announcing that topline results from the Phase 3 NOVA-2 trial of its schizophrenia drug LB-102 would be reported in the first half of 2027, earlier than previously expected.